Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1129
Abstract: Storage of trametinib tablets outside of 2‐8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability. In this open‐label, phase 1, single‐dose, randomized, 2‐treatment, 2‐period crossover study in… read more here.
Keywords: single dose; healthy volunteers; bioavailability; trametinib ... See more keywords
A sustained-release Trametinib bio-multifunction hydrogel inhibits orthodontically induced inflammatory root resorption
Sign Up to like & getrecommendations! Published in 2022 at "RSC Advances"
DOI: 10.1039/d2ra00763k
Abstract: Orthodontic tooth movement (OTM) is a bone reconstruction process. In most cases, OTM could induce root resorption as a common side effect, called orthodontically induced inflammatory root resorption (OIIRR). OIIRR affects tooth health and interferes… read more here.
Keywords: resorption; trametinib; ccod tra; root resorption ... See more keywords
Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2019.1554440
Abstract: ABSTRACT Introduction:Mitogen-activated protein kinase (MAPK) pathway is known to be involved in the tumorigenesis of cancer cells including non-small cell lung cancer (NSCLC) and kinases involved in this pathway are frequently mutated. The development of… read more here.
Keywords: combination; protein kinase; non small; cancer ... See more keywords
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1515057
Abstract: ABSTRACT Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling pathway inhibition in head… read more here.
Keywords: efficacy; mek; trametinib; tumor ... See more keywords
Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.
Sign Up to like & getrecommendations! Published in 2022 at "Human molecular genetics"
DOI: 10.1093/hmg/ddac169
Abstract: Somatic activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations have been reported in patients with arteriovenous malformations. By producing LSL-Kras (G12D); Cdh5 (PAC)-CreERT2 [iEC-Kras (G12D*)] mice, we hoped to activate KRAS within vascular endothelial… read more here.
Keywords: kras induced; kras g12d; trametinib; iec kras ... See more keywords
LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.394
Abstract: Abstract INTRODUCTION Low grade gliomas (LGG) are the most common pediatric brain tumors. Tumors not amenable to resection can recur or progress despite treatment with chemotherapy and/or radiation. Recent discovery of the activation of the… read more here.
Keywords: grade gliomas; low grade; lgg; trametinib ... See more keywords
MODL-27. MEK INHIBITION WITH TRAMETINIB SLOWS PROGRESSION OF MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN ORTHOTOPIC XENOGRAFT MURINE MODEL
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.600
Abstract: Abstract BACKGROUND Combination of surgery, chemotherapy, autologous transplantation, irradiation constitutes treatment of CNS embryonal-cell tumors (Medulloblastoma-MBL, atypical teratoid rhabdoid tumor-AT/RT). Targeted agents to improve survival and decrease side effects are necessary. We hypothesize that inhibiting… read more here.
Keywords: murine; mbl; atypical teratoid; cell ... See more keywords
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0272
Abstract: Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1–3, is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma. We… read more here.
Keywords: pazopanib; combination; inhibitor; advanced soft ... See more keywords
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-4179
Abstract: Purpose: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated… read more here.
Keywords: hsc3; yap1; resistance; trametinib ... See more keywords
Trametinib Promotes MEK Binding to the RAF-Family Pseudokinase KSR.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-138
Abstract: The MEK inhibitor trametinib caused MEK to engage KSR more efficiently than MEK engaged BRAF. read more here.
Keywords: promotes mek; ksr; trametinib; mek binding ... See more keywords
Trametinib Attenuates Delayed Rejection and Preserves Thymic Function in Rat Lung Transplantation.
Sign Up to like & getrecommendations! Published in 2019 at "American journal of respiratory cell and molecular biology"
DOI: 10.1165/rcmb.2018-0188oc
Abstract: RATIONALE Delayed immunological rejection following human lung transplantation causes chronic lung allograft dysfunction (CLAD), which is associated with high mortality. Delayed rejection may be attributable to indirect alloantigen presentation by host antigen-presenting cells (APCs); however,… read more here.
Keywords: delayed rejection; transplantation; trametinib; rejection ... See more keywords